Duration of intestinal mucosal antibody responses to poliovirus in children routinely immunised with bivalent oral polio vaccine and inactivated polio vaccine in Tanzania: A longitudinal cohort and cross-sectional study
Authors:
Preprint
Abstract
Background: Mucosal immunity is critical for preventing poliovirus transmission. Despite evidence that infant immunisation protects against poliovirus infection into adulthood, the duration of vaccine-induced intestinal antibody responses remains poorly characterised. Methods: We evaluated poliovirus type-specific neutralising activity and immunoglobulin levels in stool and serum from children in Tanzania who completed routine poliovirus vaccine series (bivalent oral polio vaccine at birth, 6, 10, and 14-weeks, and inactivated polio vaccine at 14-weeks). The study included a longitudinal cohort with four visits over 6 months and a cross-sectional sample of children recruited 1 to 108-months after vaccine series completion. Potential modification by nutritional factors, gastrointestinal infections, and environmental enteropathy was explored. Results: Among 103 longitudinal and 246 cross-sectional participants enrolled, 33% and 18% had positive poliovirus type-1 (PV1) stool neutralisation, and 66% and 56% had positive poliovirus type-3 (PV3) neutralisation 1 month after vaccination. All were seropositive for PV1 and PV3 across timepoints. Infants followed longitudinally who were stool neutralisation-positive at enrolment had no boost in neutralisation after vaccination, while those stool neutralisation-negative at enrolment experienced a weak boost at 1 month. Stool neutralisation half-life among longitudinal cohort infants was 3.4 months [95% CI 2.6-5.0] for PV1 and 1.7 months [1.4-2.3] for PV3. Moderate evidence suggested concurrent viral intestinal infections were associated with lower neutralisation responses (PV1 p=0.153; PV3 p=0.052). Conclusion: Intestinal antibody responses to poliovirus vaccination were short-lived. The impact of waning intestinal antibodies on transmission risk remains unclear and research is needed to identify vaccination strategies that induce durable mucosal immunity.Keywords
This publication has 25 references indexed in Scilit:
- Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trialsThe Lancet Microbe, 2025
- The global burden of enteric fever, 2017–2021: a systematic analysis from the global burden of disease study 2021eClinicalMedicine, 2024
- Mucosal immunity to poliovirusMucosal Immunology, 2021
- Causal Pathways from Enteropathogens to Environmental Enteropathy: Findings from the MAL-ED Birth Cohort StudyEBioMedicine, 2017
- Impact of enterovirus and other enteric pathogens on oral polio and rotavirus vaccine performance in Bangladeshi infantsVaccine, 2016
- The MAL-ED Study: A Multinational and Multidisciplinary Approach to Understand the Relationship Between Enteric Pathogens, Malnutrition, Gut Physiology, Physical Growth, Cognitive Development, and Immune Responses in Infants and Children Up to 2 Years of Age in Resource-Poor EnvironmentsClinical Infectious Diseases, 2014
- Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trialThe Lancet, 2014
- Tools for diagnosis, monitoring and screening ofSchistosomainfections utilizing lateral-flow based assays and upconverting phosphor labelsParasitology, 2014
- Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trialThe Lancet, 2010
- On the comparison of correlated proportions for clustered dataStatistics in Medicine, 1998